Cell Biology: Opening up new fronts in the fight against cholesterol
Since its discovery in 2003, the secretory protein PCSK9 has been the subject of growing interest because of its role in the degradation of low-density lipoprotein (LDL) receptors in the liver (Seidah et al., 2003). LDL receptors, which reside on the surface of liver cells, help to control cholesterol levels in the body by binding to low-density lipoprotein particles circulating in the blood and mediating their entry into the cells (Horton et al., 2009). Once inside the cells, the particles are released inside endosomes and are subsequently degraded in lysosomes, while the LDL receptors return to the cell surface to capture more low-density lipoprotein particles. PCSK9—which is short for proprotein convertase subtilisin-like type 9—prevents the LDL receptors from doing this job by binding to them and then diverting them to lysosomes for degradation. The physiological relevance of this reaction was first revealed by genetic analyses of humans with abnormal levels of lipids in their blood (Abifadel et al., 2003; Cohen et al., 2006), and confirmed in experiments using genetically manipulated mice (Maxwell and Breslow, 2004; Rashid et al., 2005; Lagace et al., 2006).
Gain-of-function mutations in PCSK9 lead to high levels of low-density lipoproteins in the blood (hypercholesterolemia) because they promote the degradation of LDL receptors, whereas loss-of-function mutations markedly reduce the levels of low-density lipoproteins. Since high levels of these lipoproteins are an important risk factor for atherosclerosis and associated coronary heart disease, finding ways to inhibit PCSK9 has become the focus of much research. Indeed, the results of recent clinical trials show that antibody-mediated inhibition of PCSK9 can reduce the levels of low-density lipoproteins in patients with hypercholesterolemia by as much as 65–70% (King, 2013). Now, in eLife, David Ginsburg of the University of Michigan and co-workers—including Xiao-Wei Chen as first author—report important insights into the transport of PCSK9 within cells (Chen et al., 2013).
PCSK9 is synthesized as a precursor in the endoplasmic reticulum (ER; Figure 1) and, like many other secretory proteins, it is subjected to post-translational modifications including glycosylation, phosphorylation, and tyrosine sulfation. Most studies to date have focused on PCSK9 once it has been secreted from cells. However, Chen and co-workers—who are based at Michigan, UC Berkeley, Wayne State University, the Cleveland Clinic and UCLA—have focused their attention on the secretion of PCSK9, and made the surprising discovery that decreased secretion of PCSK9 results in higher levels of LDL receptors, with a protein called Sec24A having a central role in the connection between the two.
Proteins are transported from the ER to the Golgi by vesicles coated with coat protein complex II (COPII), which was first identified in yeast and consists of the enzyme Sar1, and complexes made of Sec proteins (notably the heterodimeric Sec23/Sec24 complex, and the heterotetrameric Sec13/Sec31). Sec24 mediates the packaging of the protein to be transported (which is called the cargo protein) into COPII-coated vesicles, and its importance is highlighted by the observation that deletion of the Sec24 gene in yeast cells results in their death. Mammals express four paralogs or versions of Sec24—Sec24A, Sec24B, Sec24C and Sec24D—and the deletion of these paralogs in mice results in phenotypes that range from a severe neural closure defect when Sec24B is deleted, to early embryonic lethality when Sec24D is deleted (Zanetti et al., 2012). It seems likely, therefore, that each paralog mediates the inclusion of specific cargo proteins into vesicles for subsequent export from the ER.
The cargo proteins transported by COPII-coated vesicles include transmembrane proteins that span the ER membrane one or more times, as well as soluble proteins that are contained entirely within the lumen of the ER. Biochemical and crystallographic studies indicate that incorporation of a particular transmembrane cargo protein into the transport vesicle is mediated by a binding site on the Sec24 protein, which is in the cytosol, and a specific signal presented by the cargo protein (Mancias and Goldberg, 2008). How soluble proteins became incorporated into transport vesicles is not completely understood. According to the ‘bulk flow’ model, all soluble proteins become incorporated into COPII vesicles by default without selection. However, incorporation of some soluble proteins into transport vesicles is mediated by their binding to transmembrane receptors that present specific sorting signals to the Sec24 proteins in the cytosol (Figure 1).
The results of Chen and co-workers indicate that the latter of these two scenarios applies to the export of PCSK9 from the ER. They find that mice deficient in Sec24A are remarkably normal in terms of survival, development and fertility. However, characterization of these mice also led to an unexpected discovery: a deficiency of Sec24A causes abnormally low levels of low-density lipoproteins in the blood (hypocholesterolemia) as a result of elevated levels of LDL receptors in the liver.
At least three lines of evidence indicate that these high levels of LDL receptors result from decreased secretion of PCSK9. First, the levels of PCSK9 in plasma of Sec24A-deficient mice are reduced compared to wild type animals. This is accompanied by increased levels of PCSK9 within liver cells and increased expression of LDL receptors on the surface of liver cells. Second, Sec24A binds to PCSK9, even though Sec24A is a cytosolic protein and PCSK9 is confined within the lumen of the ER (Figure 1). Third, overexpression of Sec24 promotes secretion of PCSK9, whereas reducing Sec24A expression by RNA interference-mediated knockdown blunts packaging of PCSK9 into COPII vesicles.
The action of Sec24A appears to be restricted to a subset of proteins that includes PCSK9. The activation of membrane-bound transcription factors called SREBPs requires their transport from the ER to the Golgi to be mediated by the ‘escort’ protein Scap (Brown and Goldstein, 2009). Chen et al. find that SREBP activation (and thus its Scap-mediated transport from the ER to the Golgi), continues normally in the livers of Sec24A deficient mice. This is consistent with the finding that Sec24C mediates the incorporation of the Scap protein into COPII vesicles (Sun et al., 2007).
Despite these observations, enthusiasm for strategies that reduce the secretion of PCSK9 by inhibiting Sec24A should be tempered until other proteins that require Sec24A for secretion are identified. The work of Chen et al. suggests that it might be better to inhibit the putative receptor that links PCSK9 in the ER to Sec24A in the cytosol (Figure 1). Identifying this receptor and elucidating how it works will be important for two reasons: it will teach us more about the export of PCSK9 and other soluble proteins from the ER in mammals, and it might lead to the development of novel therapies to reduce the levels of low-density lipoproteins in the blood and therefore help prevent atherosclerosis and heart disease.
References
-
PCSK9: a convertase that coordinates LDL catabolismJ Lipid Res 50:S172–S177.https://doi.org/10.1194/jlr.R800091-JLR200
-
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9Proc Natl Acad Sci USA 102:5374–5379.https://doi.org/10.1073/pnas.0501652102
-
COPII and the regulation of protein sorting in mammalsNat Cell Biol 14:20–28.https://doi.org/10.1038/ncb2390
Article and author information
Author details
Publication history
- Version of Record published: April 9, 2013 (version 1)
Copyright
© 2013, DeBose-Boyd and Horton
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 593
- views
-
- 109
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Biochemistry and Chemical Biology
Truncation of the protein-protein interaction SH3 domain of the membrane remodeling Bridging Integrator 1 (BIN1, Amphiphysin 2) protein leads to centronuclear myopathy. Here, we assessed the impact of a set of naturally observed, previously uncharacterized BIN1 SH3 domain variants using conventional in vitro and cell-based assays monitoring the BIN1 interaction with dynamin 2 (DNM2) and identified potentially harmful ones that can be also tentatively connected to neuromuscular disorders. However, SH3 domains are typically promiscuous and it is expected that other, so far unknown partners of BIN1 exist besides DNM2, that also participate in the development of centronuclear myopathy. In order to shed light on these other relevant interaction partners and to get a holistic picture of the pathomechanism behind BIN1 SH3 domain variants, we used affinity interactomics. We identified hundreds of new BIN1 interaction partners proteome-wide, among which many appear to participate in cell division, suggesting a critical role of BIN1 in the regulation of mitosis. Finally, we show that the identified BIN1 mutations indeed cause proteome-wide affinity perturbation, signifying the importance of employing unbiased affinity interactomic approaches.
-
- Biochemistry and Chemical Biology
- Chromosomes and Gene Expression
Recent findings indicate that the translation elongation rate influences mRNA stability. One of the factors that has been implicated in this link between mRNA decay and translation speed is the yeast DEAD-box helicase Dhh1p. Here, we demonstrated that the human ortholog of Dhh1p, DDX6, triggers the deadenylation-dependent decay of inefficiently translated mRNAs in human cells. DDX6 interacts with the ribosome through the Phe-Asp-Phe (FDF) motif in its RecA2 domain. Furthermore, RecA2-mediated interactions and ATPase activity are both required for DDX6 to destabilize inefficiently translated mRNAs. Using ribosome profiling and RNA sequencing, we identified two classes of endogenous mRNAs that are regulated in a DDX6-dependent manner. The identified targets are either translationally regulated or regulated at the steady-state-level and either exhibit signatures of poor overall translation or of locally reduced ribosome translocation rates. Transferring the identified sequence stretches into a reporter mRNA caused translation- and DDX6-dependent degradation of the reporter mRNA. In summary, these results identify DDX6 as a crucial regulator of mRNA translation and decay triggered by slow ribosome movement and provide insights into the mechanism by which DDX6 destabilizes inefficiently translated mRNAs.